Similarly, CD8+ counts did not differ significantly across ypT or ypN stages, suggesting that reliance on a single biopsy sample for pre-treatment analysis presents a limitation, as the sampled area may not represent the overall tumor, given the variability in inflammatory cell density across different regions. This evidence concerns the gene CD8A and neoplasm.